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Abstract: Renal replacement therapy (RRT) is complicated by a chronic state of inflammation and a
high mortality risk. However, different RRT modalities can have a selective impact on markers of
inflammation and oxidative stress. We evaluated the levels of active matrix metalloproteinase
(MMP)-9 in patients undergoing two types of dialysis (high-flux dialysis (HFD) and on-line
hemodiafiltration (OL-HDF)) and in kidney transplantation (KT) recipients. Active MMP-9 was
measured by zymography and ELISA before (pre-) and after (post-) one dialysis session, and at
baseline and follow-up (7 and 14 days, and 1, 3, 6, and 12 months) after KT. Active MMP-9 decreased
post-dialysis only in HFD patients, while the levels in OL-HDF patients were already lower before
dialysis. Active MMP-9 increased at 7 and 14 days post-KT and was restored to baseline levels three
months post-KT, coinciding with an improvement in renal function and plasma creatinine. Active
MMP-9 correlated with pulse pressure as an indicator of arterial stiffness both in dialysis patients
and KT recipients. In conclusion, active MMP-9 is better controlled in OL-HDF than in HFD and is
restored to baseline levels along with stabilization of renal parameters after KT. Active MMP-9 might
act as a biomarker of arterial stiffness in RRT.
Keywords: matrix metalloproteinase-9; dialysis; on-line hemodiafiltration; high-flux dialysis; renal
replacement therapy; kidney transplantation
1. Introduction
Chronic kidney disease (CKD) is defined as abnormalities of kidney structure and/or function for
a period of at least three months, with implications for health [1]. CKD is an irreversible disorder and
often progresses to end-stage renal disease (ESRD), which is life-threatening and requires some form of
renal replacement therapy (RRT) such as dialysis or kidney transplantation (KT). Since KT is limited
by organ availability, dialysis is the most common form of RRT to remove uremic toxins in ESRD.
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There are two types of dialysis treatments that can be applied to the ESRD patient: peritoneal dialysis
and hemodialysis. Hemodialysis can be further classified depending on the membrane modality
(convective vs. diffusive). For example, high-flux dialysis (HFD) is based on the use of high diffusion
and low convection, whereas on-line hemodiafiltration (OL-HDF) is based on lower diffusion and
higher convection, enabling the removal of middle- and larger-molecular weight substances. However,
whatever the dialysis strategy used, it is only a temporary solution until the patient can undergo KT.
Patients with CKD, especially ESRD, are regarded as being at high risk of fatal and non-fatal
cardiovascular events because cardiovascular and renal disease often have similar origins and risk
factors [2]. Cardiovascular risk is particularly high for patients undergoing dialysis [3] because of
CKD-associated complications such as atherosclerosis and systemic inflammation [4]. Indeed, this
enhanced risk of atherosclerotic cardiovascular events begins from the earliest stages of CKD. Moreover,
dialysis-specific risk factors such as mineral bone disorders and excess fluid load induce vascular
calcification and hypertension, which in turn induce arterial stiffness [5], a process characterized by a
thickening of the arterial wall and a loss of elastin fiber integrity leading to a decrease in elasticity [6].
Arterial stiffness is a predictor of cardiovascular disease in dialysis and KT recipients [7,8], and is
associated with graft dysfunction and rejection [9]. Interestingly, vascular thickening tends to diminish
after KT [10] and, in fact, KT improves the longevity and quality of life of patients as compared with
long-term dialysis treatment [11], although cardiovascular risk remains higher than in the general
population [12].
The anomalous turnover of extracellular matrix components favors deleterious vascular
remodeling, which is a major mechanism underlying arterial stiffness. Matrix metalloproteinases
(MMPs) play a central role in the regulation of both physiological and pathological connective tissue
turnover. In particular, the inducible MMP-9, degrades laminin, elastin, and type IV collagen [13], which
are the main components of the glomerular basement membrane of the kidney. In fact, the exaggerated
activation of MMP-9 has been associated with an abnormal glomerular basement membrane structure
and consequent albuminuria escape in treated hypertension [14]. MMP-9 activation is triggered under
stress conditions including inflammation and oxidative stress [13] and is consequently upregulated in
inflammation-dependent conditions such as hypertension and associated with cardiovascular risk in
patients undergoing hemodialysis [15].
Although the use of MMP-9 as a marker of cardiovascular risk has been widely described, there
is a paucity of studies examining how RRT affects its activity [16]. MMP-9 can be assessed as total
MMP-9 or active MMP-9 levels measured by the MMP-9/tissue inhibitor of MMP (TIMP)-1 ratio,
zymography, or solid-phase immunoassays. Total MMP-9 abundance is, however, not a direct measure
of its activity, as both active and inactive MMP-9 are considered. Likewise, the indirect measure of
active MMP-9 using the MMP-9/TIMP-1 ratio might be inadequate because it considers that TIMP-1,
the endogenous inhibitor of MMP-9, interacts completely with MMP-9 in a 1:1 stoichiometry [17]. It is
known that reactive oxygen and nitrogen species can interact with both TIMP-1 and MMP-9, blocking
endogenous MMP-9 inhibition and activating MMP-9 constitutively [13] and, therefore, assessment of
the MMP-9/TIMP-1 ratio as an indicator of MMP-9 activation is not recommended [18], especially in
conditions of oxidative stress such as CKD or ESRD.
Given the heterogeneity in MMP-9 measurements and the gap in our knowledge on MMP-9 activity
in RRT, the aim of this study was to assess the effect of different types of RRT (HFD, OL-HDF, and KT) on
active MMP-9 measured in a direct manner by zymography and enzyme-linked immunosorbent assay
(ELISA), as well as by the direct protein interaction between MMP-9 and TIMP-1 using AlphaLISA®
technology (PerkinElmer, Waltham, MA, USA).
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2. Materials and Methods
2.1. Study Population
The study included two independent cohorts of patients receiving RRT: 32 dialysis-dependent
patients recruited for a cross-sectional analysis between November 2016 and March 2017 [19], and
46 KT recipients recruited for a longitudinal study between November 2014 and June 2016 [20,21].
The exclusion criterion for KT recipients was development of acute rejection in the first year post-KT.
Both cohorts of patients were recruited at the Nephrology Unit of the Hospital Universitario 12 de
Octubre (Madrid, Spain). Dialysis-dependent patients underwent clinical examination before dialysis,
and KT patients underwent clinical examination before transplant. Pulse pressure (PP) was determined
as the difference between systolic blood pressure (SBP) and diastolic (DBP) blood pressure [9]. Blood
samples were drawn before (pre-) and after (post-) one dialysis session, or in the case of KT at baseline
and 7 days, 14 days, 1 month, 3 months, 6 months, and 12 months post-KT. Blood samples were
collected in heparin tubes and immediately centrifuged at 2000 rpm for 10 min. Plasma samples were
stored at −80 ◦C until use.
All patients signed informed consent. The study was approved by the local ethics committee in
compliance with the guidelines of the Declaration of Helsinki.
2.2. Assessment of Active MMP-9
Active MMP-9 was assessed by zymography and ELISA. Zymography was performed under
non-reducing conditions using 10% SDS/PAGE containing 0.1% gelatin. Following electrophoresis, gels
were incubated in 500 mM Tris, 6 mM CaCl2, and stained with Coomassie Brilliant Blue R-250 (Bio-Rad,
Hercules, CA, USA). Digitalized gel images were analyzed with ImageJ software (NIH, Bethesda,
MD, USA). Quantification of active MMP-9 was performed with a commercially available ELISA kit
(QuickZyme BioSciences, Leiden, The Netherlands). Given the consistency between zymography
and ELISA, follow-up of KT patients was exclusively assessed by ELISA at 7 days, 3 months, and 12
months post-KT. In the case of dialysis-dependent patients, active MMP-9 post-dialysis was corrected
according to the weight loss during dialysis using the following equation:
Cc =
Cpost
1 +
BWpre− BWpost
0.2 ∗ BWpost
, (1)
where Cc is the corrected concentration post-dialysis, Cpost is the concentration post-dialysis, BWpre is
the body weight pre-dialysis, and BWpost is the body weight post-dialysis [22].
2.3. Assessment of Total MMP-9, Total TIMP-1, and MMP-9/TIMP-1 Interaction
Quantification of total MMP-9 and TIMP-1 was performed in KT patients at baseline, 7 days,
3 months, and 12 months post-KT using commercial ELISA Quantikine kits (R&D Systems, Minneapolis,
MN, USA). MMP-9/TIMP-1 was calculated by dividing the levels of total MMP-9 by the levels of TIMP-1.
AlphaLISA® technology was used to detect the interaction between MMP-9 and TIMP-1 following
a published protocol [18]. Briefly, AlphaLISA® acceptor beads (PerkinElmer, Waltham, MA, USA)
were conjugated with an anti-MMP-9 antibody (ThermoFisher Scientific, Waltham, MA, USA) and
then incubated with plasma samples from KT recipients and a biotinylated anti-TIMP-1 antibody
(ThermoFisher Scientific). Streptavidin-coated donor beads were then added to bind the biotinylated
anti-TIMP-1 antibody and detect the MMP-9/TIMP-1 interactions. Plates were read on an EnSpire
Multimode Microplate Reader (PerkinElmer) using an excitation wavelength of 680 nm and an emission
wavelength of 615 nm.
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2.4. Statistical Analysis
Normality of data was determined with the Kolmogorov–Smirnov test. HFD and OL-HDF groups
were compared using unpaired Student’s t-test or the Mann–Whitney U test. Categorical variables were
compared with Fisher’s exact test. Pre- and post-dialysis groups were compared using the Wilcoxon
signed-rank test, and KT follow-up groups were compared using the Friedman test. Spearman’s
rank-order correlation was used to analyze correlations. Results are expressed as mean ± SEM unless
otherwise stated, and p-values < 0.05 were considered significant. Analyses were performed using
GraphPad Prism 6 (GraphPad Software Inc., San Diego, CA, USA) and SPSS Statistics v22 (IBM,
Armonk, NY, USA).
3. Results
3.1. Clinical Characteristics
Baseline characteristics of all hemodialysis patients stratified according to the type of dialysis
applied (HDF or OL-HDF) are shown in Table 1. No differences were found in the mean age between
the two groups. Likewise, there were no differences between the HFD and OL-HDF groups for
hypertension, SBP, PP, diabetes mellitus, or N-terminal pro-brain natriuretic peptides. Dialysis-related
parameters were also the same between the groups except for the duration of dialysis. Patients in
the OL-HDF group were significantly longer on dialysis (31.4 vs. 98.4 months for HFD and OL-HDF,
respectively). There were no differences between the groups for the cause of CKD or the medication
used. The proportion of men was significantly higher in the OL-HFD group (65%) than in the HFD
group (11%). Baseline characteristics of the KT recipients are shown in Table 2.
Table 1. Baseline characteristics of dialysis patients.
All Patients (n = 32) HFD Patients (n = 9) OL-HDF Patients (n = 23) p-Value
Age (years) 60.0 ± 16,4 64.7 ± 22.0 58.2 ± 13.8 0.322
Male sex (n, %) 16 (50) 1 (11) 15 (65) 0.016
Hypertension (n, %) 25 (78) 7 (78) 18 (78) 0.999
SBP (mmHg) 128.4 ± 23.0 126.2 ± 23.2 129.3 ± 23.4 0.739
PP (mmHg) 55.5 ± 17.5 58.4 ± 14.6 54.3 ± 18.7 0.556
Diabetes mellitus (n, %) 7 (22) 2 (22) 5 (22) 0.999
NT-proBNP (pg/mL) 2565 ± 1735 2753 ± 1245 2509 ± 1881 0.769
Dialysis-related parameters
Serum creatinine (mg/dL) 7.61 ± 2.22 7.16 ± 2.22 7.78 ± 2.25 0.486
Serum albumin (g/dL) 4.05 ± 0.43 3.91 ± 0.24 4.10 ± 0.48 0.259
Potassium (mEq/L) 5.15 ± 0.90 5.06 ± 0.78 5.19 ± 0.95 0.725
Bicarbonate (mEq/L) 21.3 ± 2.9 21.2 ± 3.8 21.3 ± 2.6 0.974
Dialysis vintage (months) 79.5 ± 74.3 31.4 ± 24.5 98.4 ± 79.1 0.020
Kt/V 1.63 ± 0.24 1.68 ± 0.25 1.61 ± 0.24 0.463
eGFR (ml/min/1.73 m2) 6.92 ± 3.00 6.48 ± 2.92 7.09 ± 3.08 0.614
Residual diuresis (n, %) 15 (52) 5 (56) 10 (43) 0.699
Interdialytic urine volume (mL) 375 (163–875) 250 (100–500) 500 (175–1000) 0.518
Cause of CKD 0.547
Glomerulonephritis (n, %) 7 (22) 2 (22) 5 (22)
Diabetic nephropathy (n, %) 5 (16) 1 (11) 4 (17)
Polycystic kidney disease (n, %) 4 (12) 0 (0) 4 (17)
Hypertensive nephropathy (n, %) 2 (6) 0 (0) 2 (9)
Other or undetermined (n, %) 14 (44) 6 (67) 8 (35)
Medication
ACEi/ARB (n, %) 8 (25) 2 (22) 6 (26) 0.999
Diuretics (n, %) 3 (9) 0 (0) 3 (13) 0.541
β-blockers (n, %) 13 (41) 5 (56) 8 (35) 0.427
Cinacalcet (n, %) 3 (9) 0 (0) 3 (13) 0.541
Paricalcitol (n, %) 12 (38) 5 (56) 7 (30) 0.253
SBP: systolic blood pressure; PP: pulse pressure; NT-proBNP: N-terminal (NT)-pro B-type natriuretic peptide; Kt/V:
where K is the dialyzer urea clearance, t is the total treatment time, and V is the total volume within the body that
urea is distributed; eGFR: estimated glomerular filtration rate; CKD: chronic kidney disease; ACEi: angiotensin
converting enzyme inhibitor; ARB: angiotensin receptor blocker.
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Table 2. Baseline characteristics of kidney transplant recipients.
All Patients
(n = 46)
Age of the recipient (years) 54.6 ± 15.8
Male sex (n, %) 27 (59)
Previous kidney transplant (n, %) 4 (9)
Pretransplant dialysis (n, %) 41 (89)
Dialysis vintage (months) 21.0 ± 19.0
SBP (mmHg) 134.5 ± 14.8
PP (mmHg) 49.9 ± 12.9
Serum creatinine (mg/dL) 6.27 ± 2.56
Serum albumin (g/dL) 4.23 ± 0.52
eGFR (mL/min/1.73 m2) 9.82 ± 4.28
Donor
Male sex (n, %) 25 (54)
Age (years) 52.6 ± 14.6
Living donor (n, %) 5 (11)
Number of HLA-mismatches 5 (4–5)
Cause of CKD
IgA nephropathy 9 (20)
Glomerulonephritis 2 (4)
Diabetic nephropathy 7 (15)
Polycystic kidney disease 8 (17)
Hypertensive nephropathy 3 (7)
Other or undetermined 17 (37)
Induction therapy 38 (83)
Maintenance immunosuppression
Steroids 46 (100)
Tacrolimus 46 (100)
Mycophenolate mofetil/mycophenolic acid 42 (91)
Cyclosporine A 0 (0)
SBP: systolic blood pressure; PP: pulse pressure; eGFR: estimated glomerular filtration rate; CKD: chronic kidney
disease; HLA: human leukocyte antigen.
3.2. Dialysis Reduces Active MMP-9 Levels
We first compared the plasma levels of active MMP-9 in all dialysis patients pre- and post-dialysis.
Active MMP-9 estimated by zymography (Figure 1A) or quantified by ELISA (Figure 1B) was lower
post-dialysis than pre-dialysis, and this was significant for the ELISA analysis. Baseline plasma levels
of active MMP-9 were significantly lower in the OL-HDF group than in the HFD group, both by
zymography (Figure 1C) and ELISA (Figure 1D), and active MMP-9 levels were reduced by dialysis
only in the HFD group while OL-HDF patients’ active MMP-9 levels remained at the same level
after the dialysis process. Active MMP-9 negatively correlated with the interdialytic urine volume
(Figure 1E), in the sense that less urine volume was associated with higher MMP-9 activity.
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plasma of dialysis patients before (pre-dialysis) and after (post-dialysis) one session of dialysis. (C) 
Representative zymography gel showing plasma gelatinase MMP-9 activity (upper panel) and 
quantification (bottom panel). (D) Quantification of active MMP-9 formed by ELISA in plasma of 
dialysis patients stratified as those on high-flux dialysis (HFD) (pre- and post-dialysis) and on-line 
hemodiafiltration (OL-HDF) (pre- and post-dialysis). (E) Negative correlation between interdialytic 
urine volume and pre-dialysis active MMP-9 in dialysis patients with residual urine volume. 
Correlation was performed using Spearman’s test and a linear regression of the data is displayed. *p 
< 0.05 vs. pre-dialysis; #p < 0.05 and ##p < 0.01 vs. HFD pre-dialysis. 
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shown in Figure 2A. Active MMP-9, measured by gel zymography (Figure 2B) or quantified by ELISA 
(Figure 2C), increased significantly 7 days after KT. Active MMP-9 levels remained high 14 days after KT 
(Figure 2A,B), but thereafter decreased significantly at one month after KT, reaching levels not 
significantly different to baseline at 3 and 12 months after KT (Figure 2A–C). Active MMP-9 levels were 
related to renal function, decreasing as estimated glomerular filtration rate (eGFR) increased and plasma 
creatinine decreased (Figure 2D). 
Figure 1. Matrix metalloproteinase (MMP)-9 activity in pre- and post-dialysis according to the type of
dialysis applied. (A) Representative zymography gel showing plasma gelatinase MMP-9 activity (upper
panel) and quantification (bottom panel). (B) Quantification of active MMP-9 by ELISA in plasma of
dialysis patients before (pre-dialysis) and after (post-dialysis) one session of dialysis. (C) Representative
zymography gel showing plasma gelatinase MMP-9 activity (upper panel) and quantification (bottom
panel). (D) Quantification of active MMP-9 formed by ELISA in plasma of dialysis patients stratified as
those on high-flux dialysis (HFD) (pre- and post-dialysis) and on-line hemodiafiltration (OL-HDF) (pre-
and post-dialysis). (E) Negative correlation between interdialytic urine volume and pre-dialysis active
MMP-9 in dialysis patients with residual urine volume. Correlation was performed using Spearman’s
test and a linear regression of the data is displayed. * p < 0.05 vs. pre-dialysis; # p < 0.05 and ## p < 0.01
vs. HFD pre-dialysis.
3.3. Kidney Transplantation Increases Total and Active MMP-9 and Total TIMP-1 Levels, but Not
MMP-9:TIMP-1 Protein Interactions
Representative gel zymography of active MMP-9 in KT recipients before KT and at follow-up is
shown in Figure 2A. Active MMP-9, measured by gel zymography (Figure 2B) or quantified by ELISA
(Figure 2C), increased significantly 7 days after KT. Active MMP-9 levels remained high 14 days after
KT (Figure 2A,B), but thereafter decreased significantly at one month after KT, reaching levels not
significantly different to baseline at 3 and 12 months after KT (Figure 2A–C). Active MMP-9 levels
were related to renal function, decreasing as estimated glomerular filtration rate (eGFR) increased and
plasma creatinine decreased (Figure 2D).
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after 7 days, 3 months, and 12 months. (D) Evolution of eGFR, plasma creatinine, and active MMP-9 at 
baseline and 7 days, 3 months, and 12 months after KT. ***p < 0.001 vs. baseline and ###p < 0.001 vs. 7 days 
after KT. 
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expression or, alternatively, to its endogenous inhibition by TIMP-1, we measured total MMP-9 and 
TIMP-1 levels in KT recipients. Total MMP-9 levels increased significantly at 7 days after KT relative 
to baseline levels, but significantly decreased at 3 and 12 months after KT (Figure 3A). A similar 
pattern was observed for TIMP-1 levels, with a significant increase at 7 days after KT and a return to 
baseline levels at 3 months (Figure 3B). However, TIMP-1 levels continued to decrease at 12 months 
after KT and were significantly lower than baseline levels at this time (Figure 3B). To indirectly 
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between both molecules, we used the AlphaLISA protocol to measure MMP-9:TIMP-1 protein 
interactions [18]. No changes in MMP-9:TIMP-1 interactions were found until 12 months after KT, 
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Figure 2. MMP-9 activity profile before and after kidney transplantation. (A) Representative
zymography gel showing plasma gelatinase MMP-9 activity. (B) Quantification of active MMP-9 by
zymography in plasma of kidney transplantation (KT) patients at baseline (before KT) and after 7
and 14 days, and 1, 3, 6, and 12 months. (C) Quantification of active MMP-9 by ELISA in plasma of
KT patients at baseline and after 7 days, 3 months, and 12 months. (D) Evolution of eGFR, plasma
creatinine, and active MMP-9 at baseline and 7 days, 3 months, and 12 months after KT. *** p < 0.001 vs.
baseline and ### p < 0.001 vs. 7 days after KT.
To evaluate whether the changes in active MMP-9 abundance were due to changes in its expression
or, alternatively, to its endogenous inhibition by TIMP-1, we measured total MMP-9 and TIMP-1 levels
in KT recipients. Total MMP-9 levels increased significantly at 7 days after KT relative to baseline
levels, but significantly decreased at 3 and 12 months after KT (Figure 3A). A similar pattern was
observed for TIMP-1 levels, with a significant increase at 7 days after KT and a return to baseline levels
at 3 months (Figure 3B). However, TIMP-1 levels continued to decrease at 12 months after KT and
were significantly lower than baseline levels at this time (Figure 3B). To indirectly estimate MMP-9
activity and following the line of the majority of clinical studies, we calculated the MMP-9/TIMP-1
ratio, which revealed a significant increase in the MMP-9/TIMP-1 ratio over baseline levels at 7 days
after KT (Figure 3C). The ratio decreased to baseline levels 3 months after KT but increased 12 months
after KT, reaching an intermediate level (Figure 3C). To confirm the interaction between both molecules,
we used the AlphaLISA protocol to measure MMP-9:TIMP-1 protein interactions [18]. No changes in
MMP-9:TIMP-1 interactions were found until 12 months after KT, when the interaction was significantly
higher than at baseline (Figure 3D).
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Figure 3. Total protein MMP-9 and tissue inhibitor of MMP (TIMP)-1 levels, MMP-9/TIMP-1 ratio,
and MMP-9:TIMP-1 interactions before and after KT. (A) Total MMP-9 protein levels (B) and total
TIMP-1 protein levels quantified by ELISA at baseline and at 7 days, 3 months, and 12 months after
KT. (C) MMP-9/TIMP-1 ratio estimation. (D) AlphaLISA® MMP-9:TIMP-1 interaction immunoassay
expressed as binding relative luminescence units (RLUs). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. baseline;
# p < 0.05, ## p < 0.01 and ### p < 0.001 vs. 7 days after KT; and ϕ p < 0.05, ϕϕ p < 0.01, ϕϕϕ p < 0.001
vs. 3 months after KT.
3.4. Active MMP-9 Positively Correlates with Arterial Stiffness in RRT Patients, but Not with Systolic
Blood Pressure
We examined for correlations between active MMP-9 levels, SBP, and the arterial stiffness PP
parameters in patients u dergoing RRT. No c rrelation was found betwe n acti -9 and SBP in
the dialysis or KT cohorts (Figu e 4A,B). However, found a positive significant correlation between
active MMP-9 levels and PP in both dialysis an KT cohorts (Figure 4A,B).
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regression of the data is displayed. 
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Figure 4. Correlation between MMP-9 activity and systolic blood pressure (SBP) and pulse pressure (PP)
at pre-dialysis and before KT. (A) No association of MMP-9 activity with SBP (in green) and a positive
significant correlation with PP (in blue) in dialysis patients in pre-dialysis. (B) No association of MMP-9
activity with SBP (in green) and a positive significant correlation with PP (in blue) in KT recipients
before KT (baseline). Correlation was performed using Spearman’s test and a linear regression of the
data is displayed.
4. Discussion
Our study shows that: (i) patients undergoing OL-HDF have lower levels of active MMP-9
compared with those undergoing HFD; (ii) active MMP-9 increases early post-KT at 7 and 14 days and
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stabilizes in parallel with renal markers at 3 months after KT; and (iii) active MMP-9 is associated with
arterial stiffness measured by PP in RRT (pre-dialysis and before KT).
Renal dysfunction is characterized by a uremic state that aggravates as renal function declines,
reaching its maximum in ESRD. This state is intimately associated with all-cause mortality and
especially with cardiovascular morbidity and mortality. Undoubtedly, RRT improves the lifespan
and the quality of life of patients with ESRD. Among RRT patients, KT significantly improves the
quality of life compared with dialysis, but the access to renal transplants is limited and not all ESRD
patients can undergo a surgical procedure. Although dialysis is the cornerstone of RRT, it is also
associated with a state of chronic inflammation and oxidative stress [23]. Dialysis per se triggers an
increase in oxidative stress and inflammation because of incompatibilities with the dialysis membrane,
which activates circulating leukocytes, and also because low-molecular weight antioxidant systems are
filtered and therefore eliminated during the procedure. In addition, the type of dialysis used directly
influences the oxidative status of the patients. Indeed, recent studies demonstrate that patients under
OL-HDF have less inflammation, endothelial damage, and oxidative stress [19,24,25], which could be
associated with the improved prognosis in this group [26,27]. The reduction in middle-molecules is
associated with the preservation of residual renal function [28], which decreases the mortality risk in
dialysis [29] and is improved in OL-HDF [30]. The systemic activation of MMP-9 is a marker of a lasting
inflammatory state that is inherent to renal disease, as has been demonstrated even with adequate
pharmacological treatment in patients with CKD [14,31]. In the case of ESRD, and especially dialysis,
there are conflicting results on the levels of MMP-9 in the pre- and post-dialysis states [32,33]. This
could be due to the different types of dialysis membranes [34,35], or to the type of dialysis itself [19,25].
We demonstrate herein that active MMP-9 is cleared during dialysis when the type of dialysis is not
considered, but a decrease in active MMP-9 is only seen in HFD. Other authors have described a
decrease in total MMP-9 during OL-HDF, but not during other hemodialysis [36]. Nevertheless, total
MMP-9 does not necessarily correlate with active MMP-9, and the measurement of active MMP-9 is a
more direct assessment of its pathophysiological activity [14]. The fact that only HFD effectively clears
active MMP-9 might suggest that HFD is more efficient than OL-HDF; however, pre-dialysis active
MMP-9 was significantly lower in the OL-HDF group than in HFD patients, indicating that the levels
of active MMP-9 are better controlled in patients under OL-HDF. Moreover, residual renal function is
associated with lower inflammation in OL-HDF [37,38]. Supporting this, we also observed that active
MMP-9 is lower in patients with greater interdialytic urine volume, which is superior to eGFR as an
estimate of residual renal function in dialysis [28].
KT is the only curative treatment for ESRD and long-term survival is significantly greater after KT
than after dialysis. Despite its benefits, however, KT is not without risks, such as the inevitable ischemia
and reperfusion (I/R) injury, which triggers several processes such as immune system activation,
endothelial dysfunction, and cell death. Likewise, I/R induces morphological changes in the kidney
that lead to fibrosis, as shown by the elevation of fibrosis-related biomarkers in the kidney of patients
with chronic allograft nephropathy [39]. By contrast, a well-known benefit of KT is the normalization
of inflammatory and oxidative stress markers [40]. For example, the C-terminal agrin fragment, a
biomarker for kidney function and a breakdown product of agrin, the major proteoglycan of the
glomerular basement membrane, strongly correlates with creatinine and eGFR and is stabilized at
1–3 months after KT [41]. In the same line, interleukin 6, a well-known precursor of MMP-9 activation,
shows a burst of activity one week after KT before stabilizing [42]. In the present study, we demonstrate
that systemic active MMP-9 levels increase one week after KT, but rapidly and significantly decrease
from the second week after surgery. We speculate that the increase in active MMP-9 evident one week
after KT likely originates from neutrophils in response to leukocyte activation inherent to I/R processes.
This is supported by experimental studies demonstrating that MMP-9 promotes mononuclear cell
infiltration in a rat model of early allograft nephropathy [43].
The peak in active MMP-9 observed early post-KT (after 7 and 14 days) might be due to an
increase in total MMP-9 or an enhancement in the enzyme activation by the inflammatory environment.
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MMP-9 is synthesized as a zymogen with a covered zinc-containing active site. Other MMPs and
MMP-9 itself cleave the peptide chain that covers the active site in physiological conditions. However,
reactive oxygen and nitrogen species can pathologically expose the active site by binding to the zinc
ion. Reactive oxygen and nitrogen species can also bind to TIMP-1 and hamper the physiological
inhibition of MMP-9. Indeed, MMP-9:TIMP-1 interactions are reduced under conditions of increased
oxidative stress and can therefore mask the results obtained from the surrogate marker of MMP-9
activity, the MMP-9/TIMP-1 ratio [18]. Given the increase in oxidative stress associated with I/R, we
aimed to investigate whether the peak in active MMP-9 was due to the pathological activation of
MMP-9 or to an increase in MMP-9 protein levels. Our results indicate that the peak in active MMP-9
was in fact due to an increase in total MMP-9 expression, and the results of the MMP-9/TIMP-1 ratio
indicate the same. However, the reduction in TIMP-1 levels at 12 months post-KT leads to an increase
in the MMP-9/TIMP-1 ratio, erroneously suggesting increased MMP-9 activity. Indeed, active MMP-9
is unaltered 12 months post-KT because the MMP-9:TIMP-1 interaction is increased, supporting the
importance of measuring active MMP-9 rather than the MMP-9/TIMP-1 ratio. The suggested increase
in active MMP-9 by the MMP-9/TIMP-1 ratio indicates an increase in mortality risk [44]. However,
total and real active MMP-9 do not vary, and TIMP-1, which is also associated with mortality [45],
is reduced. Therefore, the patients might actually have a reduced risk of mortality as the KT becomes
more stable.
Finally, arterial stiffness increases SBP by wave reflection and decreases DBP, which increases
PP, a marker of large artery stiffness [46]. Arterial stiffness is attenuated after KT as compared with
hemodialysis [9,47–50], and is subject to donor age, living kidney donation, and mean blood pressure [5].
Our study shows for the first time, to our knowledge, that active MMP-9 correlates with PP in patients
treated with RRT. We found that, independently of the type of dialysis, PP is lower as the levels of
active MMP-9 decline. A decrease in active MMP-9 suggests that arterial stiffness might be reduced in
patients undergoing OL-HDF. However, we failed to find differences in PP between groups of patients
on the different types of dialysis, in accord with results from other groups describing that arterial
stiffness is not different between hemodialysis and HDF [5]. We also found that baseline active MMP-9
correlates with PP before KT, supporting the idea that a reduction in active MMP-9 levels in ESRD
patients is needed to ameliorate arterial stiffness.
The main limitation of the present study was the small population of dialysis patients. More
studies are needed in order to confirm our results, but this pilot study is the first step in assessing the
insights of arterial stiffness in different types of dialysis.
5. Conclusions
Active MMP-9 is lower in OL-HDF than in HFD and shows a peak in KT recipients after I/R in
the early post-KT stages (7 and 14 days). However, the peak in active MMP-9 is resolved in parallel
with the restoration of renal function, indicating that MMP-9 activity is likely a surrogate of I/R injury.
In both contexts—dialysis and KT—active MMP-9 is associated with PP in pre-dialysis and just before
KT, indicating that MMP-9 is a marker of vascular dysfunction in patients undergoing RRT.
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